Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes

Journal of Molecular Histology

Volumn 35, Issue 8-9, 2004, Pages 857-863

  Alexandrakis, Michael G ^a   Passam, Freda H ^b   Kyriakou, Despina S ^c   Dambaki, Constantina ^a   Katrinakis, George ^a   Tsirakis, George ^a   Konsolas, John ^d   Stathopoulos, Efstathios N ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^d General Hospital of Rhodes   (Greece)

Author keywords

Angiogenesis; Ki 67; MDS; MIB 1 labeling index; Microvascular density; Proliferation

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 6; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; BIOPSY; BLOOD; BONE MARROW; METABOLISM; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; FEMALE; HUMANS; INTERLEUKIN-6; KI-67 ANTIGEN; MALE; MICROCIRCULATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 16644399523     PISSN: 15672379     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10735-004-2341-0     Document Type: Article

References (35)

1. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96: 2240-2245.
2. Albitar M (2001) Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol 106: 170-176.
3. Alexandrakis M, Coulocheri S, Xylouri I, Ganotakis E, Eliakis P, Karkavitsas N, Eliopoulos G (1998) Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes. Haematologia (Budap) 29: 13-24.
4. Aul C, Giagounidis A, Germing U, Ganser A (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Am J Hematol 81: 485-497.
5. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C. (1982). Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199.
6. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C, Cox C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocylic, alypical chronic myeloid, and chronic myelomonocylic leukaemia. Br J Haematol 87: 746-754.
7. Bennett J (2000) The World Health Organization (WHO) classification of acute leukemias and the myelodysplastic syndromes. Int J Hematol 72: 131-133.
8. Belli C, Acevedo S, Bengio R, Arrossagaray G, Watman N, Rolssi N, Garcia J, Flore G, Goldztein S, Larripa I (2002) Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica 87: 9-16.
9. Brown D, Gatter K (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489-503.
10. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters R, Serve H, Berdel W, Kienast J (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636.
11. Di Raimondo F, Palumbo GA, Molica S, Giustolisi R (2001) Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 106: 177-183.
12. Fiedler W, Suciu E, Wittlief C, Ostertag W, Hossfeld D (1990) Mechanisms of growth factor expression in acute myeloid leukemia (AML) Leukemia 4: 459-461.
13. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133: 1710-1715.
14. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Muft G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
15. Herold M, Schmalzl F, Zwierzina H (1992) Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res 16: 585-588.
16. Kanavaros P, Stefanaki K, Rontogianni D, Darivianaki K, Vlychou M, Papadaki E, Eliopoulos G, Bakiri M, Matsouka C, Kakolyris S, Georgoulias V (1999) Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders. Clin Exp Pathol 47: 231-238.
17. Korkolopoulou P, Apostolidou E, Pavlopoulos P, Kavantzas N, Vyniou N, Thymara I, Terpos E, Patsouris E, Yataganas X, Davaris P (2001) Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 15: 1369-1376.
18. Kubbutat M, Key G, Duchrow M, Schluter C, Flad H, Gerdes J (1994) Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein). J Clin Pathol 47: 524-528.
19. Leary A, Ikebuchi K, Hirai Y, Wong G, Yang Y, Clark S, Ogawa M (1988) Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha. Blood 71: 1759-1763.
20. Moehler T, Neben K, Ho A, Goldschmidt H (2001) Angiogenesis in hematologic malignancies. Ann Hematol 80: 695-705.
21. Musolino C, Calabro L, Bellomo G, Martello F, Loteta B, pezzano C, Rizzo V, Alonci A (2000) Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 69: 159-163.
22. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, Pittermann E, Pfeilstocker M (2000) Myelodysplastic syndromes, from the French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98: 2935-2941.
23. Ota T, Hino M, Yamane T, Ota K, Mugitani A, Park K, Im T, Takubo T, Tatsumi N (1998) Interleukin-6 may play an important role in thrombopoiesis: a case of leukemic transformation from myelodysplastic syndrome. Ann Hematol 77: 243-244.
24. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel W, Mesters R (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95: 2637-2644.
25. Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K (2004) Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Eur J Haematol 72: 410-415.
26. Parker J, Mufti G, Rasool F, Mijovic A, Devereux S, Pagliuca A (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96: 3932-3938.
27. Pellegrini W, Facchetti F, Marocolo D, Salvi L, Capucci A, Tironi A, Rossi G (1995) Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections. Histopathology 27: 397-405.
28. Perez-Atayde A, Sallan S, Tedrow U, Connors S, Allred E, Folkman J (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150: 815-821.
29. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci P, Buffa R, Lambertenghi-Deliliers G, Pezzella F (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81: 1398-1401.
30. Raza A, Gezer S, Mundle S, Gao X, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86, 268-276.
31. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M (2000) Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 110: 584-590.
32. White D, Smith A, Smith J (1994) Assessment of proliferative activity in leukaemic bone marrow using the monoclonal antibody Ki-67. J Clin Pathol 47: 209-213.
33. Willemze R, Fibbe W, Falkenburg J, Kluin-Nelemans J, Kluin P, Landegent J (1993) Biology and treatment of myelodysplastic syndromes-developments in the past decade. Ann Hematol 66: 107-115.
34. Yi F, Wang B, Liu X (1993) The significance of Ki-67, BrdU and OKT9 expression in determination of myelodysplastic syndromes by use of APAAP technique. J Tongji Med Univ 13: 30-33.
35. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P, Raza A (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115: 881-894.